Awaiting development: Guidance and quality standards

Showing 21 to 30 of 323

Guidance and quality standards awaiting development
Title	Type
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]	Technology appraisal guidance
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]	Technology appraisal guidance
Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]	Technology appraisal guidance
Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]	Technology appraisal guidance
Atrasentan for treating primary IgA nephropathy [ID6558]	Technology appraisal guidance
Avexitide for treating hypoglycaemia after bariatric surgery [TSID12233]	Technology appraisal guidance
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]	Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]	Technology appraisal guidance
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]	Technology appraisal guidance
Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]	Technology appraisal guidance